Impact of Hydroxychloroquin/Azithromycin Protocol on COVID-19 Case-Fatality Rate Reduction in Algeria

Ahmed Youssef Kada; Kheireddine Abdelouahed Bouyoucef; Kouider Sahraoui

Loading...

Impact of Hydroxychloroquin/Azithromycin Protocol on COVID-19 Case-Fatality Rate Reduction in Algeria

;
;

African Journal of Biology and Medical Research

Vol. 3Issue 22020pp. 66–72Published 12 June 2020

1,596Views

520Downloads

Metrics

Share Link

𝕏

Cite this

Citation unavailable for this article.

Abstract:

This study aimed to demonstrate the effectiveness of hydroxychloroquin/ azithromycin protocol in Algeria, in particular after its extension to all patients diagnosed COVID-19 positive on RT-PCR test. We were able to illustrate this fact graphically, but not to prove it statistically, indeed in the 7 days which followed generalization of therapeutic protocol, case fatality rate decrease and doubling time increase, thus confirming the impact of wide and early prescription of hydroxychloroquin/azithromycin protocol.

Keywords:6

Copyrights

Authors retain copyright in their articles and have unrestricted rights to reuse, republish, archive, share, and distribute their work after publication.
All articles are published open access under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence, which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, including for commercial purposes, provided appropriate credit is given to the original author(s) and source.

Loading…

Disclaimer/Publisher’s Note

The statements, opinions and data contained in this publication are solely those of the author(s) and contributor(s) and not of AB Journals or its editors. AB Journals remains neutral and accepts no responsibility for any injury or damage resulting from ideas, methods, instructions or products referred to in the content.

Copyrights

Authors retain copyright in their articles and have unrestricted rights to reuse, republish, archive, share, and distribute their work after publication.
All articles are published open access under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence, which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, including for commercial purposes, provided appropriate credit is given to the original author(s) and source.